Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes.

Eric P Hoffman, George Washington University
Valerie Riddle
Maxime A Siegler
Daniel Dickerson
Miroslav Backonja
William G Kramer
Kanneboyina Nagaraju, George Washington University
Heather Gordish-Dressman, George Washington University
Jesse M Damsker
John M McCall

Abstract